Yeo B, Turner NC, Jones A. Clinical Review: An update on the medical management of breast cancer. BMJ Jun 9;348:g3608. ICR B

Transcript

1 International Breast Cancer Symposium, June 2014, Vol. 1, No dxy.cnmedlive.cn Yeo B, Turner NC, Jones A. Clinical Review: An update on the medical management of breast cancer. BMJ Jun 9;348:g ICR 3 BMJ 2008 HER2 HER2 PubMed 2013 [1] 1 [2] 1 30 Cancer Research UK [1] 2008 [3,4] NHS 4773 [2] B [5] 1mm [6] SLNB SLNB ALND ALND ALND SLNB ALND [7] SLN ALNDZ0011 [8] 800 SLNB 27% ALND 6.3 SLNBALND SLNB ALND 1 2 SLN ALND [9] [10] SLN ALND 1.3

2 International Breast Cancer Symposium, June 2014, Vol. 1, No. 3 HER2 Adjuvant Online PREDICT Ki-67 [11] 2 2 B A Oncotype DX 21 3Mammaprint 70 NICE Oncotype DX A B 2 3 [12] A BHER2 A BHER2 HER2 HER2 HER2 50% HER2 HER2 3 Oncotype DX %95%[CI]5%10% T Ki HER

3 International Breast Cancer Symposium, June 2014, Vol. 1, No % 5 41% 31% [13] ATAC BIG %9.6% 12.6%P0.001 [14] 2 D [15] 23 [14] [16] % 0.57P0.001 [17] 5 5 ATLAS 7000 [18] P P [19] % 4.1% % 1.6% [18] 6953 ATTom [20] ATLAS ATTom [20] [21] Oncotype DX TAILORx NCT MINDACT NCT [22] 1% MINDACT 2.4 HER2 15% HER2 [23] HER P P [24,25] 3% [26] HER2 20% 30%HER2 HER2 HER2 HER [27] % 21.9%P % 8.8% P HER2 [28]

4 International Breast Cancer Symposium, June 2014, Vol. 1, No. 3 [29] HER2 / 4 A [30] HER2 [31] 4.1 mtor [32] mtor P0.001 [33] HER2 mtor IIII 4.2 HER2 HER2 4.3 HER2 HER P0.046 [34] [35] HER2 III 800 HER3 HER2 HER P0.001 [36] 0.66P [37] 4 HER2 HER2 HER2 ACLEOPATRA [36] HER2 48%BEMILIA [39] T-DM1 T DM1 T-DM1 T-DM1 HER2 - [38] III EMILIA T-DM P P [39] HER2 3 [39] 5 60%80% [40,41] [42] RANK [43] 2000 [44] D

5 International Breast Cancer Symposium, June 2014, Vol. 1, No %1% [45] 6 HER2 [46] CyberKnifeGamma Knife [47] 7 [48,49] HER2 HER2 HER2 [1] Cancer Research UK. Breast cancer incidence statistics. /incidence/uk-breast-cancer-incidence-statistics#trends [2] Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Lancet. 2012;380(9855): [3] Turner NC, Jones AL. Management of breast cancer--part I. BMJ. 2008;337:a421. [4] Turner NC, Jones AL. Management of breast cancer--part II. BMJ. 2008;337:a540. [5] Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347(16): [6] Moran MS, Schnitt SJ, Giuliano AE, et al. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with wholebreast irradiation in stages I and II invasive breast cancer. J Clin Oncol. 2014;32(14): [7] Kim T, Giuliano AE, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer. 2006;106(1):4-16. [8] Giuliano AE, McCall L, Beitsch P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010;252(3): ;discussion [9] Lyman GH, Temin S, Edge SB, et al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2014;32 (13): [10] Rutgers EJ, Donker M, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer patients: final analysis of the EORTC AMAROS trial (10981/22023). J Clin Oncol. 2013;31(18_suppl):LBA1001. [11] Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797): [12] Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003;100(14): [13] Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472): [14] Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010;28(3): [15] Kanis JA, Burlet N, Cooper C, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2008;19(4): [16] Davies C, Godwin J, Gray R, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378 (9793): [17] Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptorpositive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97(17): [18] Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869): [19] Al-Mubarak M, Tibau A, Templeton AJ, et al. Extended adjuvant tamoxifen for early breast cancer: a meta-analysis. PLoS One. 2014; 9(2):e [20] Gray RG, Rea D, Handley K, et al. attom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol. 2013;31(18_suppl):5. [21] Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Clarke M, Coates AS, et al. Adjuvant chemotherapy in oestrogenreceptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet. 2008;371(9606): [22] Goldstein LJ, O'Neill A, Sparano JA, et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E J Clin Oncol. 2008;26(25): [23] Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/ neu oncogene. Science. 1987;235(4785): [24] Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16): [25] Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007;369(9555): [26] Suter TM, Procter M, van Veldhuisen DJ, et al. Trastuzumabassociated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol. 2007;25(25): [27] Coleman R, Gnant M, Paterson A, et al. Effects of bisphosphonate treatment on recurrence and cause-specific mortality in women with early breast cancer: A meta-analysis of individual patient data from randomised trials. Cancer Res. 2013;73(24_Suppl):S4-07. [28] Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997;15(7): [29] von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30(15):

6 International Breast Cancer Symposium, June 2014, Vol. 1, No. 3 [30] Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010;28(20): [31] Giordano SH, Buzdar AU, Smith TL, et al. Is breast cancer survival improving? Cancer. 2004;100(1): [32] Miller TW, Balko JM, Fox EM, et al. ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discov. 2011;1(4): [33] Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6): [34] Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344 (11): [35] Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355(26): [36] Baselga J, Cortés J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012; 366(2): [37] Swain SM, Kim SB, Cortés J, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013;14(6): [38] Lewis Phillips GD, Li G, Dugger DL, Crocker LM, et al. Targeting HER2-positive breast cancer with trastuzumab-dm1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008;68(22): [39] Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367 (19): [40] Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer. 1987;55(1): [41] Hortobagyi GN. Novel approaches to the management of bone metastases in patients with breast cancer. Semin Oncol. 2002;29 (3 Suppl 11): [42] Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev. 2005;(3):CD [43] Baron R, Ferrari S, Russell RG. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. 2011;48(4): [44] Stopeck A. Denosumab findings in metastatic breast cancer. Clin Adv Hematol Oncol. 2010;8(3): [45] Saad F, Lattouf JB. Bisphosphonates: prevention of bone metastases in prostate cancer. Recent Results Cancer Res. 2012;192: [46] Lin NU, Winer EP. Brain metastases: the HER2 paradigm. Clin Cancer Res. 2007;13(6): [47] Sperduto PW, Chao ST, Sneed PK, et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys. 2010;77 (3): [48] Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418): [49] Curtis C, Shah SP, Chin SF, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486(7403): jcbd@medmail.com.cn jcbd@medmail.com.cn